Telomir Pharmaceuticals, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation FL
Business Address 100 SE 2ND ST, MIAMI, FL, 33131
Mailing Address 100 SE 2ND ST, MIAMI, FL, 33131
Phone 786-396-6723
Fiscal Year End 1231
EIN 872606031
Financial Overview
FY2025
-$16.53M
Net Income
$7.34M
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 22, 2025 | View on SEC |
| 8-K Current report of material events | December 17, 2025 | View on SEC |
| 8-K Current report of material events | November 24, 2025 | View on SEC |
Material Events
8-K Acquisition March 27, 2026
High Impact
- Strategic acquisition of Teli Pharmaceuticals to accelerate clinical development
- Expansion of telomere-lengthening pipeline to advance FDA filings
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.